Denali Therapeutics Regains Full Rights to Dementia Drug Following Takeda Partnership Termination

MT Newswires Live04-06

Denali Therapeutics (DNLI) said Friday it regained full control of its investigational frontotemporal dementia therapy after Takeda Pharmaceuticals (TAK) terminated their joint development agreement.

Takeda ended the commercialization partnership for strategic reasons rather than any concerns regarding the medication's safety or effectiveness, the company said.

Denali Therapeutics will continue advancing the Phase 1/2 study, which recently completed enrollment with 40 participants and is expected to generate biomarker results by the end of this year, it said.

Preliminary data from healthy volunteers demonstrated that the treatment successfully increased targeted protein levels in the brain without producing any significant safety signals, Denali said.

Shares of Denali Therapeutics were up 1.6%, and shares of Takeda were down 2% in Monday premarket activity.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2625673846?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-06 17:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2625673846","market":"nz","top_or_hot":-1,"title":"Denali Therapeutics Regains Full Rights to Dementia Drug Following Takeda Partnership Termination","media":"MT Newswires Live","content":"<html><body><p> Denali <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (DNLI) said Friday it regained full control of its investigational frontotemporal dementia therapy after Takeda Pharmaceuticals (TAK) terminated their joint development agreement.</p><p>Takeda ended the commercialization partnership for strategic reasons rather than any concerns regarding the medication's safety or effectiveness, the company said.</p><p>Denali Therapeutics will continue advancing the Phase 1/2 study, which recently completed enrollment with 40 participants and is expected to generate biomarker results by the end of this year, it said.</p><p>Preliminary data from healthy volunteers demonstrated that the treatment successfully increased targeted protein levels in the brain without producing any significant safety signals, Denali said.</p><p>Shares of Denali Therapeutics were up 1.6%, and shares of Takeda were down 2% in Monday premarket activity.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Denali Therapeutics Regains Full Rights to Dementia Drug Following Takeda Partnership Termination</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDenali Therapeutics Regains Full Rights to Dementia Drug Following Takeda Partnership Termination\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-04-06 17:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Denali <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (DNLI) said Friday it regained full control of its investigational frontotemporal dementia therapy after Takeda Pharmaceuticals (TAK) terminated their joint development agreement.</p><p>Takeda ended the commercialization partnership for strategic reasons rather than any concerns regarding the medication's safety or effectiveness, the company said.</p><p>Denali Therapeutics will continue advancing the Phase 1/2 study, which recently completed enrollment with 40 participants and is expected to generate biomarker results by the end of this year, it said.</p><p>Preliminary data from healthy volunteers demonstrated that the treatment successfully increased targeted protein levels in the brain without producing any significant safety signals, Denali said.</p><p>Shares of Denali Therapeutics were up 1.6%, and shares of Takeda were down 2% in Monday premarket activity.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DNLI","symbol_name":"Denali Therapeutics Inc.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2625673846","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2625673846","pubTimestamp":1775467681,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Denali Therapeutics  said Friday it regained full control of its investigational frontotemporal dementia therapy after Takeda Pharmaceuticals  terminated their joint development agreement.Takeda ended the commercialization partnership for strategic reasons rather than any concerns regarding the medication's safety or effectiveness, the company said.Denali Therapeutics will continue advancing the Phase 1/2 study, which recently completed enrollment with 40 participants and is expected to generate biomarker results by the end of this year, it said.Preliminary data from healthy volunteers demonstrated that the treatment successfully increased targeted protein levels in the brain without producing any significant safety signals, Denali said.Shares of Denali Therapeutics were up 1.6%, and shares of Takeda were down 2% in Monday premarket activity.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"DNLI":"Denali Therapeutics Inc.","BK4007":"制药","BK4539":"次新股","LENZ":"Therapeutics","TAK":"武田制药","BK4548":"巴美列捷福持仓","BK4535":"淡马锡持仓","BK4139":"生物科技"},"translate_title":"武田终止合作关系后，Denali Therapeutics重新获得痴呆症药物的全部权利","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1.5,"TAK":1,"DNLI":1},"content_text":"Denali Therapeutics (DNLI) said Friday it regained full control of its investigational frontotemporal dementia therapy after Takeda Pharmaceuticals (TAK) terminated their joint development agreement.Takeda ended the commercialization partnership for strategic reasons rather than any concerns regarding the medication's safety or effectiveness, the company said.Denali Therapeutics will continue advancing the Phase 1/2 study, which recently completed enrollment with 40 participants and is expected to generate biomarker results by the end of this year, it said.Preliminary data from healthy volunteers demonstrated that the treatment successfully increased targeted protein levels in the brain without producing any significant safety signals, Denali said.Shares of Denali Therapeutics were up 1.6%, and shares of Takeda were down 2% in Monday premarket activity.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2625673846","isCrawlerRequest":true}